“ Recent
Ektapharm GLP1 loading and release findings have demonstrated significant
improvement to API loading efficiency with superior initial burst control and
long term [monthly] release properties compared to the leading approved [API]
type II diabetes mellitus (T2DM) products.
Ektapharm’s self-CAP™ system has now demonstrated a safe,
solvent–free model with far lower production yield losses,
and improved active component trapping, resulting in much lower
production costs for numerous existing and new parenteral
API’s with significantly improved depot delivery properties .
The
self-CAP™ system can not only reduce the initial burst and the varying injection
delivery depot size required but can ultimately achieve superior patient
comfort & compliance with the potential for vastly improved efficacy.”
For more information contact:
Fred Foley
fred.foley@comcast.net
Ektapharm currently on hold due to intellectual property matters
ReplyDeletePatents were re-filed
ReplyDelete